New s Br iefs

BY BILL HELTZEL / bheltzel@westfairinc.com

Regeneron reports $3.16B Q2 revenues

Tarrytown-based Regeneron Pharmaceuticals today reported that its second quarter 2023 revenues increased 11% compared with the second quarter of 2022. The second quarter 2023 revenues were $3.16 billion. Net income reported using generally accepted accounting principles was $968 million for the second quarter.

“Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth,” said Leonard S. Schleifer, the company’s president and CEO.

The company said it spent $1.08 billion on research and development in the second quarter of the year, compared with $794 million in the second quarter of last year. It said that global net sales of the drug Dupixent, which are recorded